<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li></ul>An update from Alphamab Oncology ( (HK:9966) ) is now available. Alphamab Oncology announced that its breakthrough HER2-targeting ADC, JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the FDA for advanced platinum-resistant ovarian and related cancers, signaling the therapy’s clinical potential amid significant unmet treatment needs. This milestone reinforces Alphamab’s position in oncology innovation, as it accelerates JSKN003’s regulatory review and clinical development globally, benefiting cancer patients while enhancing the company’s international credibility. The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page. More about Alphamab Oncology Alphamab Oncology is a leading biopharmaceutical company based in China, specializing in innovative monoclonal and bispecific antibodies, ADCs, and multi-functional protein engineering for oncology treatment. With proprietary technology platforms, the company has built a highly differentiated pipeline, including products in advanced clinical trial stages, aimed at improving global cancer treatment. Average Trading Volume: 2,923,078 Technical Sentiment Signal: Buy Current Market Cap: HK$10.05B For an in-depth examination of 9966 stock, go to TipRanks’ Overview page.</div>

09966

Alphamab Oncology’s JSKN003 Receives FDA Breakthrough Therapy Designation